BA
The Boeing Company
BA's outlook is improving, though it still trails on the overall score.
ECG
Everus Construction Group, Inc.
ECG has the edge over BA overall, supported by stronger modeled upside and stronger valuation.
BA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
BA's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
ECG Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Healthy |
ECG's revenue, profitability, cash flow and balance sheet are all currently healthy.
BA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $172 | — |
| Cheap | 51x | $496 | +189% |
| Fair | 82x | $790 | +360% |
| Expensive | 91x | $876 | +411% |
Historical ranges are pointers, not guarantees.
BA has the edge over ECG in the historical PE scenario, which offers more potential upside but is not a forecast.
ECG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $87.17 | — |
| Current | 15x | $87.17 | — |
| Cheap | 20x | $113 | +29% |
| Fair | 25x | $142 | +63% |
| Expensive | 31x | $174 | +100% |
Historical ranges are pointers, not guarantees.
ECG's PE is in its cheap range at 15x. If earnings grow as analysts expect, today's price would be 13x next year's earnings.
BA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect BA to return to profit, with revenue growing. However, they disagree widely on these estimates.
ECG Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ECG, with profitability improving. However, they disagree widely on these estimates.
BA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $9.66 | +$23.38 |
| Q2 2026 | $2.78 | +$19.33 |
| Q1 2026 | $2.53 | +$20.49 |
| Q4 2025 | $2.48 | +$20.84 |
| Q3 2025 | -$13.72 | -$0.83 |
| Q2 2025 | -$16.55 | -$10.93 |
| Q1 2025 | -$17.96 | -$14.42 |
| Q4 2024 | -$18.36 | -$14.69 |
BA has returned to profit: it earned $9.66 per share over the past year, after losing money the year before.
ECG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.68 | +18% |
| Q3 2026 | $5.66 | +60% |
| Q2 2026 | $4.98 | +53% |
| Q1 2026 | $4.37 | +47% |
| Q4 2025 | $3.95 | +35% |
| Q3 2025 | $3.54 | +37% |
| Q2 2025 | $3.25 | +31% |
| Q1 2025 | $2.98 | +20% |
| Q4 2024 | $2.92 | +19% |
ECG has the edge over BA on earnings, with more consistent year-over-year improvement.
BA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2B | +3.9% |
| Q2 2026 | $24.6B | +8% |
| Q1 2026 | $22.2B | +14% |
| Q4 2025 | $23.9B | +57% |
| Q3 2025 | $23.3B | +30% |
| Q2 2025 | $22.7B | +35% |
| Q1 2025 | $19.5B | +18% |
| Q4 2024 | $15.2B | -31% |
BA's revenue has grown year over year for seven quarters in a row: $24.2B last quarter, up 3.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.5% | +22 points |
| Q2 2026 | 0.6% | +1.4 points |
| Q1 2026 | 2% | -0.3 points |
| Q4 2025 | 37% | +61 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -0.8% | +5.7 points |
| Q1 2025 | 2.4% | +2.9 points |
| Q4 2024 | -25% | -26 points |
BA's operating margin was 1.5% last quarter, up 22 points from the same quarter a year ago.
ECG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +40% |
| Q2 2026 | $1.2B | +34% |
| Q1 2026 | $1B | +25% |
| Q4 2025 | $1B | +33% |
| Q3 2025 | $986.8M | +30% |
| Q2 2025 | $921.5M | +31% |
| Q1 2025 | $826.6M | +32% |
| Q4 2024 | $759.6M | +19% |
ECG has the edge over BA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.8% | +1.5 points |
| Q2 2026 | 9.1% | +1.2 points |
| Q1 2026 | 7.5% | +1.3 points |
| Q4 2025 | 6.8% | +0.8 points |
| Q3 2025 | 7.3% | +0.3 points |
| Q2 2025 | 7.9% | +0.6 points |
| Q1 2025 | 6.2% | 0 points |
| Q4 2024 | 6.1% | -2 points |
ECG has the edge over BA on profitability, with a higher operating margin.
BA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $464M | +95% |
| Q2 2026 | $631M | +$831M |
| Q1 2026 | -$1.5B | +$836M |
| Q4 2025 | $375M | +$4.5B |
| Q3 2025 | $238M | +$2.2B |
| Q2 2025 | -$200M | +$4.1B |
| Q1 2025 | -$2.3B | +$1.6B |
| Q4 2024 | -$4.1B | -239% |
BA has the edge over ECG on cash flow, with more consistent year-over-year improvement.
ECG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $52.7M | -20% |
| Q2 2026 | $33M | +169% |
| Q1 2026 | $128.2M | +$139.6M |
| Q4 2025 | $23.5M | -65% |
| Q2 2025 | $12.3M | +$37.7M |
| Q1 2025 | -$11.4M | -190% |
| Q4 2024 | $66.9M | -35% |
| Q2 2024 | -$25.4M | -$6M |
ECG generated $237M in free cash flow over the past year, up 78% from the year before.
BA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.1M shares |
| 1 year | +4.3% | +32.8M shares |
| 3 years | +31% | +186M shares |
| 5 years | +35% | +204M shares |
| Available history | +40% | +227M shares |
BA has 793M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
ECG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +19K shares |
| 1 year | +0.2% | +102K shares |
| 3 years | +0.5% | +267K shares |
ECG has the edge over BA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
BA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q4 2025 | 6.9x | High |
| Q2 2024 | 361.8x | High |
| Q1 2024 | 36.1x | High |
| Q4 2023 | 36.4x | High |
| Q3 2023 | 96.1x | High |
BA's net debt is about 3.0 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
ECG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2024 | 1.5x | Healthy |
| Q1 2024 | 0.0x | Very low |
| Q4 2023 | 0.9x | Very low |
ECG has the edge over BA on leverage, with a lower net debt burden relative to earnings.
BA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 9.6 | Oversold |
BA's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
ECG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.4 | Neutral |
| Stochastic | 15.6 | Oversold |
ECG's weekly RSI is 36 (neutral) and its Stochastic is 16 (oversold).
BA PE vs Industrials Sector
| Metric | BA | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 24x | 26% below |
| PE % | 0 | 58 | 58 pts below |
BA is trading at 18x earnings, a 26% discount to the Industrials sector's median of 24x, though its earnings don't support one.
ECG PE vs Industrials Sector
| Metric | ECG | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 24x | 36% below |
| PE % | 9 | 30 | 21 pts below |
ECG has the edge over BA on valuation relative to its sector.
BA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $184.6 | 7.1% below |
| 20 week MA | $203.8 | 16% below |
| 50 week MA | $215.5 | 20% below |
| 100 week MA | $205.9 | 17% below |
| 200 week MA | $200.6 | 14% below |
ECG has stronger trend alignment. BA is above 0 of 5 weekly averages versus ECG above 0 of 4.
ECG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.2 | 16% below |
| 20 week MA | $118.5 | 26% below |
| 50 week MA | $119.1 | 27% below |
| 100 week MA | $92.3 | 5.5% below |
ECG is in a downtrend: it's below all four of its weekly moving averages, and 5.5% below its 100-week average.
BA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.1 | $217.2 | -34% |
| 2021 | $217.2 | $204.2 | -6% |
| 2022 | $204.2 | $189.1 | -7.4% |
| 2023 | $189.1 | $260.7 | +38% |
| 2024 | $260.7 | $180.7 | -31% |
| 2025 | $180.7 | $216.4 | +20% |
| 2026 YTD | $216.4 | $171.6 | -21% |
BA has finished lower in four of the last six years. It's down 21% so far in 2026.
ECG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $52.5 | $69.9 | +33% |
| 2025 | $69.9 | $90.1 | +29% |
| 2026 YTD | $90.1 | $87.2 | -3.2% |
ECG has the edge over BA on returns for 2026, with the stronger performance.